Academic Journal
Molecular characteristics and antimicrobial susceptibility profiling of carbapenem-resistant Pseudomonas aeruginosa clinical isolates in Korea: Implications for novel β-lactam therapy.
| Τίτλος: | Molecular characteristics and antimicrobial susceptibility profiling of carbapenem-resistant Pseudomonas aeruginosa clinical isolates in Korea: Implications for novel β-lactam therapy. |
|---|---|
| Συγγραφείς: | Sung YH; Institute of Emerging Infectious Diseases, Korea University, Seoul, Republic of Korea., Park SM; Institute of Emerging Infectious Diseases, Korea University, Seoul, Republic of Korea., Lee HJ; Institute of Emerging Infectious Diseases, Korea University, Seoul, Republic of Korea., Yoon YK; Institute of Emerging Infectious Diseases, Korea University, Seoul, Republic of Korea; Division of Infectious Diseases, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea. Electronic address: young7912@korea.ac.kr. |
| Πηγή: | Journal of global antimicrobial resistance [J Glob Antimicrob Resist] 2026 Sep; Vol. 50, pp. 209-216. Date of Electronic Publication: 2026 Jul 08. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Published by Elsevier Ltd. on behalf of International Society of Chemotherapy for Infection and Cancer Country of Publication: Netherlands NLM ID: 101622459 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-7173 (Electronic) Linking ISSN: 22137165 NLM ISO Abbreviation: J Glob Antimicrob Resist Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Amsterdam : Published by Elsevier Ltd. on behalf of International Society of Chemotherapy for Infection and Cancer |
| Ιατρικοί όροι (MeSH): | Pseudomonas aeruginosa*/drug effects , Pseudomonas aeruginosa*/genetics , Pseudomonas aeruginosa*/isolation & purification , Pseudomonas aeruginosa*/classification , Pseudomonas Infections*/microbiology , Pseudomonas Infections*/epidemiology , Pseudomonas Infections*/drug therapy , Anti-Bacterial Agents*/pharmacology , Carbapenems*/pharmacology , beta-Lactams*/pharmacology , beta-Lactam Resistance*, Republic of Korea/epidemiology ; Cephalosporins/pharmacology ; Ceftazidime/pharmacology ; Azabicyclo Compounds/pharmacology ; beta-Lactamases/genetics ; Bacterial Proteins/genetics ; Drug Resistance, Multiple, Bacterial/genetics ; Aztreonam/pharmacology ; Tazobactam/pharmacology ; Humans ; Microbial Sensitivity Tests ; Cefiderocol ; Multilocus Sequence Typing ; Third Generation Cephalosporins ; Molecular Epidemiology ; Drug Combinations |
| Περίληψη: | Background: This study investigated the molecular epidemiology, cross-resistance to novel antibiotics, and clonal distribution of carbapenem-resistant Pseudomonas aeruginosa (CRPA) clinical isolates. Methods: Forty-three CRPA isolates were collected from sterile clinical specimens in the Republic of Korea between 2015 and 2025. Susceptibility to 14 antibiotics was assessed in vitro by broth microdilution. Carbapenem-resistance mechanisms were characterized by using polymerase chain reaction, real-time quantitative reverse transcription polymerase chain reaction, and sequencing. Clonal diversity and epidemiological trends were examined by multilocus sequence typing. Results: Among the 43 CRPA isolates, the susceptibility rates were 88.4% for both aztreonam-avibactam and cefiderocol, compared with 46.5% for ceftolozane-tazobactam and 39.5% for ceftazidime-avibactam. Among the 22 difficult-to-treat resistance P. aeruginosa isolates, susceptibility rates were 77.3% for aztreonam-avibactam and 86.4% for cefiderocol. Carbapenemase genes were detected in 46.5% of isolates, predominantly bla Conclusions: CRPA exhibited multifactorial resistance driven by oprD disruption and bla (Copyright © 2026 The Author(s). Published by Elsevier Ltd.. All rights reserved.) |
| Contributed Indexing: | Keywords: Carbapenem resistance; Drug resistance; Multilocus sequence typing; Pseudomonas aeruginosa; β-lactams |
| Substance Nomenclature: | 0 (Anti-Bacterial Agents) SZ34OMG6E8 (Cefiderocol) 0 (Carbapenems) 0 (Cephalosporins) 9M416Z9QNR (Ceftazidime) 0 (Third Generation Cephalosporins) 0 (Azabicyclo Compounds) 0 (avibactam, ceftazidime drug combination) EC 3.5.2.6 (beta-Lactamases) 0 (ceftolozane, tazobactam drug combination) 0 (beta-Lactams) 0 (Drug Combinations) 0 (Bacterial Proteins) G2B4VE5GH8 (Aztreonam) SE10G96M8W (Tazobactam) |
| Entry Date(s): | Date Created: 20260708 Date Completed: 20260923 Latest Revision: 20260923 |
| Update Code: | 20260924 |
| DOI: | 10.1016/j.jgar.2026.06.023 |
| PMID: | 42419643 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 2213-7173 |
|---|---|
| DOI: | 10.1016/j.jgar.2026.06.023 |